Clinical Trial Update: IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial of the IDH1 inhibitor ivosidenib (AG-120) in IDH1-mutated myelodysplastic syndromes (also listed for acute myeloid leukemia); the study is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Ivosidenib (AG-120) (ivosidenib)

Snippet

Sponsor: Groupe Francophone des Myelodysplasies | Conditions: Myelodysplastic Syndromes, Acute Myeloid Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING